Literature DB >> 9226005

Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

S Aquaro1, C F Perno, E Balestra, J Balzarini, A Cenci, M Francesconi, S Panti, F Serra, N Villani, R Caliò.   

Abstract

Several anti-HIV drugs acting on different steps of virus replication were tested in our experimental model of primary monocyte/macrophages; the results were compared with the activity found in lymphocytes. Nucleoside analogues (AZT, ddI, ddC, d4T, PMEA, 3TC etc.) show greater activity in macrophages (M/M) than in lymphocytes. In particular, the EC50 of AZT, ddC, and ddI in M/M is 2- to 100-fold lower than that found in lymphocytes. This greater efficacy of nucleoside analogues in M/M depends on the enhancement of their chain-terminating activity by the low levels of endogenous deoxynucleoside-triphosphates (dNTP) usually found in resting cells such as M/M. Non-nucleoside reverse transcriptase inhibitors (NNRTI) do not act as chain terminators (thus their antiviral effect is not related to the intracellular concentrations of dNTP); as a consequence the activity of TSAO, HEPT, TIBO, and other NNRTI tested in M/M is similar to that found in lymphocytes. Regarding inhibitors of binding and fusion of HIV, we found that their anti-HIV activity is markedly decreased (or even nullified) when M/M are treated with cytokine activators of M/M function and enhancers of HIV replication. More relevant from a clinical standpoint, protease inhibitors are able to inhibit HIV replication in chronically infected macrophages (i.e., cells carrying the proviral genome already integrated in the host genome). All other inhibitors of late stage of virus life cycle tested (antisense-rev, anti-tat, interferon-alpha and -gamma, phosphorothioate analogues, GLQ-223, etc.) were totally inactive in chronically infected macrophages. The different effects of various classes of HIV inhibitors in lymphocytes and macrophages suggests that AIDS therapy should consider all aspects of the pathogenesis of HIV infection and must be restricted to drugs, or combinations of drugs, active against both lymphocytes and M/M in all body compartments where the virus hides and replicates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226005     DOI: 10.1002/jlb.62.1.138

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  25 in total

Review 1.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  A pseudovirus system for the testing of antiviral activity of compounds in different cell lines.

Authors:  S V Cheresiz; I V Grigoryev; E A Semenova; V O Pustylnyak; V V Vlasov; A G Pokrovsky
Journal:  Dokl Biochem Biophys       Date:  2010-12-24       Impact factor: 0.788

3.  Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets.

Authors:  Theodore J Cory; Hui He; Lee C Winchester; Santosh Kumar; Courtney V Fletcher
Journal:  Pharm Res       Date:  2016-07-18       Impact factor: 4.200

4.  Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.

Authors:  Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 5.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 6.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

7.  Longitudinal analysis of monocyte/macrophage infection in simian immunodeficiency virus-infected, CD8+ T-cell-depleted macaques that develop lentiviral encephalitis.

Authors:  Stephanie J Bissel; Guoji Wang; Anita M Trichel; Michael Murphey-Corb; Clayton A Wiley
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Authors:  Jennifer A Fulcher; Yon Hwangbo; Rafael Zioni; David Nickle; Xudong Lin; Laura Heath; James I Mullins; Lawrence Corey; Tuofu Zhu
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Authors:  Sarah K Ho; Elena E Perez; Stephanie L Rose; Roxana M Coman; Amanda C Lowe; Wei Hou; Changxing Ma; Robert M Lawrence; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.